JP2004537550A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537550A5
JP2004537550A5 JP2003513558A JP2003513558A JP2004537550A5 JP 2004537550 A5 JP2004537550 A5 JP 2004537550A5 JP 2003513558 A JP2003513558 A JP 2003513558A JP 2003513558 A JP2003513558 A JP 2003513558A JP 2004537550 A5 JP2004537550 A5 JP 2004537550A5
Authority
JP
Japan
Prior art keywords
group
salt
structural formula
acid
pharmaceutically suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003513558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4598390B2 (ja
JP2004537550A (ja
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed filed Critical
Priority claimed from PCT/HU2002/000067 external-priority patent/WO2003007951A1/en
Publication of JP2004537550A publication Critical patent/JP2004537550A/ja
Publication of JP2004537550A5 publication Critical patent/JP2004537550A5/ja
Application granted granted Critical
Publication of JP4598390B2 publication Critical patent/JP4598390B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003513558A 2001-07-17 2002-07-10 糖尿病予防、または糖尿病治療のための相乗作用の薬学的組成物 Expired - Fee Related JP4598390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2004537550A JP2004537550A (ja) 2004-12-16
JP2004537550A5 true JP2004537550A5 (https=) 2009-06-18
JP4598390B2 JP4598390B2 (ja) 2010-12-15

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003513558A Expired - Fee Related JP4598390B2 (ja) 2001-07-17 2002-07-10 糖尿病予防、または糖尿病治療のための相乗作用の薬学的組成物

Country Status (21)

Country Link
US (2) US7635674B2 (https=)
EP (1) EP1408966B1 (https=)
JP (1) JP4598390B2 (https=)
KR (1) KR100920560B1 (https=)
CN (1) CN1270713C (https=)
AT (1) ATE386523T1 (https=)
AU (1) AU2002354884B2 (https=)
BR (1) BR0210744A (https=)
CA (2) CA2682251A1 (https=)
CY (1) CY1107939T1 (https=)
DE (1) DE60225143T2 (https=)
DK (1) DK1408966T3 (https=)
ES (1) ES2300460T3 (https=)
IL (2) IL159412A0 (https=)
MX (1) MXPA04000324A (https=)
NO (1) NO20040153L (https=)
NZ (1) NZ531155A (https=)
PL (1) PL205826B1 (https=)
PT (1) PT1408966E (https=)
RU (1) RU2311907C2 (https=)
WO (1) WO2003007951A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044531A2 (en) * 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
WO2012142458A1 (en) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN115916202A (zh) * 2020-05-27 2023-04-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c9底物的并行给药
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Similar Documents

Publication Publication Date Title
US8048873B2 (en) Synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP2004537550A5 (https=)
AU2005299808B2 (en) Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
CN100348189C (zh) DPP-IV抑制剂与PPAR-α化合物的组合
KR100506428B1 (ko) 대사 장애, 특히 당뇨병 또는 당뇨병 관련 질환 또는증상의 치료 방법
EP1248604A2 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP2006523668A (ja) 糖尿病の予防又は治療のためのシクレタニンを含有する相乗作用の薬学的組合せ
US20140142145A1 (en) Combinations comprising a dipeptidylpeptidase - iv inhibitor
US20100056460A1 (en) Combination of organic compounds
CN1840195A (zh) 一种用于预防或治疗糖尿病的协同药物组合物
HUP0400762A2 (hu) Gyógyászati készítmény a diabetesz megelőzésére vagy kezelésére
JP4588448B2 (ja) PPARγアゴニストによる治療に伴う体重増加を治療するためのPPARαアゴニストの使用